Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis

Rajnish Mehrotra, Daniel Cukor, Mark Unruh, Tessa Rue, Patrick Heagerty, Scott D. Cohen, Laura M. Dember, Yaminette Diaz-Linhart, Amelia Dubovsky, Tom Greene, Nancy Grote, Nancy Kutner, Madhukar H. Trivedi, Davin K. Quinn, Nishaver Halen, Steven D. Weisbord, Bessie A. Young, Paul L. Kimmel, S. Susan Hedayati

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Background: Although depression is common among patients receiving maintenance hemodialysis, data on their acceptance of treatment and on the comparative efficacy of various therapies are limited. Objective: To determine the effect of an engagement interview on treatment acceptance (phase 1) and to compare the efficacy of cognitive behavioral therapy (CBT) versus sertraline (phase 2) for treating depression in patients receiving hemodialysis. Design: Multicenter, parallel-group, open-label, randomized controlled trial. (ClinicalTrials.gov: NCT02358343) Setting: 41 dialysis facilities in 3 U.S. metropolitan areas. Participants: Patients who had been receiving hemodialysis for at least 3 months and had a Beck Depression Inventory-II score of 15 or greater; 184 patients participated in phase 1, and 120 subsequently participated in phase 2. Intervention: Engagement interview versus control visit (phase 1) and 12 weeks of CBT delivered in the dialysis facility versus sertraline treatment (phase 2). Measurements: The primary outcome for phase 1 was the proportion of participants who started depression treatment within 28 days. For phase 2, the primary outcome was depressive symptoms measured by the Quick Inventory of Depressive Symptoms Clinician-Rated (QIDS-C) at 12 weeks. Results: The proportion of participants who initiated treatment after the engagement or control visit did not differ (66% vs. 64%, respectively; P = 0.77; estimated risk difference, 2.1 [95% CI, _12.1 to 16.4]). Compared with CBT, sertraline treatment resulted in lower QIDS-C depression scores at 12 weeks (effect estimate, _1.84 [CI, _3.54 to _0.13]; P = 0.035). Adverse events were more frequent in the sertraline than the CBT group. Limitation: No randomized comparison was made with no treatment, and persistence of treatment effect was not assessed. Conclusion: An engagement interview with patients receiving maintenance hemodialysis had no effect on their acceptance of treatment for depression. After 12 weeks of treatment, depression scores were modestly better with sertraline treatment than with CBT. Primary Funding Source: Patient-Centered Outcomes Research Institute, Dialysis Clinic, Kidney Research Institute, and National Institute of Diabetes and Digestive and Kidney Diseases.

Original languageEnglish (US)
Pages (from-to)369-379
Number of pages11
JournalAnnals of internal medicine
Volume170
Issue number6
StatePublished - Jan 1 2019
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis'. Together they form a unique fingerprint.

  • Cite this

    Mehrotra, R., Cukor, D., Unruh, M., Rue, T., Heagerty, P., Cohen, S. D., Dember, L. M., Diaz-Linhart, Y., Dubovsky, A., Greene, T., Grote, N., Kutner, N., Trivedi, M. H., Quinn, D. K., Halen, N., Weisbord, S. D., Young, B. A., Kimmel, P. L., & Hedayati, S. S. (2019). Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis. Annals of internal medicine, 170(6), 369-379.